Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/detail.php on line 234

Warning: in_array() expects parameter 2 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 82

Warning: array_push() expects parameter 1 to be array, null given in /home/pharmalicensing/public_html/inc_stats.php on line 85
Pharmalicensing | Life Science's Global Technology Marketplace
Save this technology
close
Save to Existing Project
Save to a New Project
EG-Mirotin: First-in-Class Recombinant Polypeptide Novel Subcutaneous Drug Containing RGD-motif Targeted to Suppress Edema and Vascular Leakage for Non-proliferative Diabetic Retinopathy
Korea Health Industry Development Institute (KHIDI) South Korea flag South Korea
Abstract ID:
EG-Mirotin is a RGD-motif containing human recombinant polypeptide (compound name: EGT022 / 58 amino acids / MW: 6.1-kDa). First in Class novel subcutaneous drug targeted to suppress edema and vascular leakage in abnormal retinal microvasculature through ...
Contact Heajin Jung
Participants
You
Email me a copy of this message
MECHANISM OF ACTION
EG-Mirotin, a human recombinant protein, stabilizes and normalizes abnormal and partially damaged blood vessels. The mechanistic action of EG-Mirotin not only treats the fundamental symptoms of

- EG-Mirotin is a RGD-motif containing human recombinant polypeptide (compound name:
EGT022 / 58 amino acids / MW: 6.1-kDa).

- First in Class novel subcutaneous drug targeted to suppress edema and vascular leakage in
abnormal retinal microvasculature through that normalization and stabilization of damaged retinal
microvasculature.

- Pre-clinical toxicity studies were successfully completed both in-house and in Europe
(Switzerland) with no signs of toxicity and/or genotoxicity. Additional studies confirmed there were
no undesirable angiogenesis and effects on tumor growth. Pre-clinical efficacy studies were
conducted in both the Oxygen-Induced Retinopathy model and Streptozotocin-induced diabetic
rat model. Retinal flat mount and angiography results have demonstrated formation of stabilized
and mature retinal vasculature, and Optical Coherence Tomography (OCT) measurements have
shown a statistically significant reduction in macular edema.

- Phase I safety studies conducted in Europe (Netherlands) was successful. Treatment with EGMirotin
in single and multiple doses was well tolerated in all subjects (both healthy and diabetic
patients).

- Phase IIa proof-of-concept studies are currently being conducted in Europe (France).


- Laser Photocoagulation has been widely used to treat eye diseases, but only covers Proliferative
Diabetic Retinopathy and Age-related Macular Degeneration. Drugs such as anti-VEGF and
steroids are available, but vary in efficacy/side effects, and are usually for late-stage Diabetic
Retinopathy.

- First in Class novel subcutaneous therapeutic for Non-proliferative Diabetic Retinopathy that is
competitive in terms of both route of administration and cost versus current alternate treatments.


- Novel sub-cutaneous therapeutic for Diabetic Retinopathy (Non-proliferative Diabetic Retinopathy / NPDR)

- Targeted to suppress edema and vascular leakage in abnormal capillaries in NPDR patients

GO PREMIUM TO GET PATENT INFORMATION
Type of Business Relationship Sought
Patent Pending
FEATURED
Last Updated Jun 2016
Technology Type THERAPEUTIC
Phase of Development PRECLINICAL
GOVERNMENT INSTITUTE